Opioid-Free Analgesia for Supratentorial Craniotomies: A Systematic Review.

BACKGROUND: Post-craniotomy pain can be severe and is often undermanaged. Opioids can interfere with neurological monitoring and are associated with adverse effects. This systematic review aimed to identify measures of opioid-free analgesia and compare their effectiveness with opioid analgesia for post-craniotomy pain in patients with supratentorial tumors. METHODS: EMBASE, MEDLINE, and Cochrane databases were searched from their inception to February 14, 2017, for randomized controlled trials (RCTs) evaluating opioid versus non-opioid analgesia post-supratentorial craniotomy. Two reviewers independently carried out study selection and data extraction. Risk of bias assessment was performed using the Cochrane Collaboration's tool. Outcomes were pain control (changes to pain scores or use of rescue analgesia) and adverse effects. Considering the number of studies and heterogeneity, a narrative synthesis was done without pooling and results were summarized using tables. Non-opioids were assessed for the potential to be equivalent to opioid-based analgesics for pain relief and adverse effects. RESULTS: Of 467 RCTs, 4 met our inclusion criteria (n = 186 patients). Patients with scalp blocks (2 RCTs) had less post-operative nausea and vomiting (PONV), but scalp block was not superior to morphine for analgesia. Acetaminophen (1 RCT) was less likely to induce PONV but provided inadequate pain relief compared to morphine and sufentanil. Dexmedetomidine (1 RCT) was not superior to remifentanil for analgesia although it delayed time to rescue analgesia. CONCLUSIONS: Limited evidence suggests that scalp blocks and dexmedetomidine have the potential to eliminate the need for opioid analgesia. Multimodal analgesia should be considered as significant opioid-sparing effects have been shown.

Analgésie sans opioïdes dans les craniotomies supratentorielles: revue systématique. Contexte: La douleur post-craniotomie peut être sévère et n'est souvent pas maintenue. Les opioïdes peuvent interférer avec la surveillance neurologique et sont associés à des effets indésirables. Cette revue systématique visait à identifier les mesures d'analgésie sans opioïdes et à comparer leur efficacité à celle des analgésiques opioïdes pour le traitement de la douleur post-craniotomie chez les patients atteints de tumeurs supratentorielles. Méthodes: Les bases de données EMBASE, MEDLINE et Cochrane ont été explorées depuis leur création jusqu'au 14 février 2017 dans le cadre d'essais contrôlés randomisés (ECR) évaluant l'analgésie opioïde ou non opioïde après la craniotomie supratentorielle. Deux examinateurs ont indépendamment sélectionné les études et extrait les données. L'évaluation du risque de biais a été réalisée à l'aide de l'outil Cochrane Collaboration. Les résultats ont été un contrôle de la douleur (modification des scores de douleur ou l'utilisation d'une analgésie de secours) et des effets indésirables. Compte tenu du nombre d'études et de l'hétérogénéité, une synthèse narrative a été réalisée sans regroupement et les résultats ont été résumés à l'aide de tableaux. Les non-opioïdes ont été évalués pour leur potentiel équivalent aux analgésiques à base d'opioïdes pour le soulagement de la douleur et les effets indésirables. Résultats: Sur 467 ECR, 4 répondaient à nos critères d'inclusion (n = 186 patients). Les patients avec des blocs de cuir chevelu 14 (2 ECR) avaient moins de nausées et de vomissements postopératoires (NVPO), mais le bloc de cuir chevelu n'était pas supérieur à la morphine pour l'analgésie. L'acétaminophène (1 ECR) était moins susceptible d'induire des NVPO, mais ne soulageait pas suffisamment la douleur par rapport à la morphine et au sufentanil. La dexmédétomidine (1 ECR) n'était pas supérieure au rémifentanil pour l'analgésie, bien qu'elle ait retardé le délai de récupération de l'analgésie. Conclusions: Des preuves limitées suggèrent que les blocs du cuir chevelu et la dexmédétomidine pourraient éliminer le besoin d'une analgésie opioïde. Une analgésie multimodale doit être considérée, car des effets importants, qui permettent d'épargner les opioïdes, ont été démontrés.

Total Duration of Breastfeeding, Vitamin D Supplementation, and Serum Levels of 25-Hydroxyvitamin D.

OBJECTIVES: To determine the association between total breastfeeding duration and serum 25-hydroxyvitamin D (25-OHD) and to explore whether vitamin D supplementation influences this association. METHODS: We conducted a cross-sectional study of healthy children between September 2011 and August 2013 through the TARGet Kids! primary health care research network. Of the 4533 eligible children, we included only the 2508 who had 25-OHD measured. We assessed adjusted associations of total breastfeeding duration (in months) with serum 25-OHD and in supplemented versus nonsupplemented children, with the odds of 25-OHD less than 20 nanograms per milliliter. RESULTS: Each 1-month increase in total breastfeeding duration was associated with a 0.12 nanograms per milliliter lower median serum 25-OHD (95% confidence interval [CI] = -0.21 ng/mL, -0.02 ng/mL) among children who were not supplemented. The odds of serum 25-OHD less than 20 nanograms per milliliter increased by 6% (odds ratio [OR] = 1.06; 95% CI = 1.03, 1.10) for every 1-month increase in total breastfeeding duration among nonsupplemented children. The interaction between vitamin D supplementation, duration of breastfeeding, and median serum 25-OHD was statistically significant (P = .04). CONCLUSIONS: Breastfed children who were not supplemented, particularly those breastfed more than 1 year, appear to have lower vitamin D status. Vitamin D supplementation may mitigate this risk. These findings support recommendations for supplementation during breastfeeding of any duration.

The association between socioeconomic status and survival among children with Hodgkin and non-Hodgkin lymphomas in a universal health care system.

BACKGROUND: The association between socioeconomic status (SES) and cancer survival has been studied extensively in adults. However, little is known about this relationship in the pediatric population, specifically in jurisdictions with universal health care insurance programs. Our aim was to determine whether lower SES is associated with poorer survival in pediatric Hodgkin (HL) and non-Hodgkin lymphoma (NHL) patients in Ontario. PROCEDURE: All incident cases of HL and NHL in children between 0 and 14 years old diagnosed in Ontario between January 1st, 1985 and December 31st, 2006 were identified through the Pediatric Oncology Group of Ontario Networked Information System. Neighborhood income quintile and material deprivation quintile at diagnosis were used as proxies for SES. Cox proportional hazards regressions were used to assess the association between SES and the risk of event-free or overall survival. RESULTS: A total of 692 patients were included in the analysis: 302 HL and 390 NHL. SES was not associated with survival (overall or event-free) among HL and NHL patients (P > 0.05 for all four comparisons, i.e., HL/NHL, EFS/OS) after adjustment for age, sex, period of diagnosis, and disease stage. There were no differences in the distribution of disease stage across SES strata at the time of diagnosis. Similarly, the distribution of deaths among long-term survivors (survived ≥5 years from diagnosis) did not differ across SES strata (P > 0.05). CONCLUSIONS: SES was not associated with risk of death among pediatric HL and NHL patients in Ontario. This was consistent through the cancer trajectory, including diagnosis, treatment, and survivorship.

Factors associated with dental care utilization in early childhood.

OBJECTIVES: To identify sociodemographic, dietary, and biological factors associated with families who do not receive dental care in early childhood and to identify risk factors associated with having cavities among children who receive early dental care. METHODS: A cross-sectional study of healthy Canadian children seen for primary health care between September 2011 and January 2013 was conducted through the TARGet Kids! practice-based research network in Toronto, Canada. Adjusted logistic regression was used to determine factors associated with children who were not seen by a dentist in early childhood and to determine risk factors associated with having dental cavities among children who received early dental care. RESULTS: Of the 2505 children included in the analysis, <1% were seen by a dentist by 1 year of age. Older children were less likely to have never been to the dentist (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.87-0.90). Low family income (OR, 2.73; 95% CI, 1.47-5.06), prolonged bottle use (OR, 1.43; 95% CI, 1.03-2.00), and higher intakes of sweetened drinks (OR, 1.20; 95% CI, 1.01-1.42) were associated with increased risk for never having been to the dentist. Among those who had been to the dentist, older children (OR, 1.04; 95% CI, 1.03-1.05), children of low income families (OR, 1.90; 95% CI, 1.17-3.10), and those of East Asian maternal ethnicity (OR, 1.91; 95% CI, 1.10-3.29) were more likely to have dental cavities. CONCLUSIONS: Among healthy urban children seen by a primary care provider, those most susceptible to cavities were least likely to receive early dental care. These findings support the need for publicly funded universal early preventive dental care and underscore the importance for primary care physicians to promote dental care in early childhood.

Differential survival improvement for patients 20-29 years of age with acute lymphoblastic leukemia.

OBJECTIVE: To compare improvement in survival from 1986 to 2009 for acute lymphoblastic leukemia (ALL) patients 1-14, 15-19 and 20-29 years in Ontario and United States. METHODS: This population-based analysis used data from Ontario Cancer Registry (OCR) and Surveillance Epidemiology and End Results (SEER). RESULTS: In OCR, there was steady improvement in survival by period of diagnosis in all three age groups. In SEER, there was no improvement in survival for patients aged 20-29 years. CONCLUSIONS: Survival in Ontario and the United States has improved for patients with ALL aged 1-19 years. However, survival has improved among patients aged 20-29 years only in Ontario.